01:18 PM EDT, 10/21/2025 (MT Newswires) -- Stifel Canada has raised its one year price target on DRI Healthcare Trust (DHT-UN.TO) by $1, to $20, and reiterated its Buy rating, after the company announced Monday a Synthetic Royalty transaction for interest in Veligrotug by Viridian Therapeutics and the treatment of Thyroid Eye Disease (TED).

The transaction is the second pre-FDA approved deal for DRI, following a successful sebetralstat/Ekterly FDA-approval in July, writes analyst Justin Keywood. Veligrotug is to have a catalyst-rich NTM with a Biologics Licesnse Application (BLA) and FDA-submission (intravenous application), expected imminently, followed by top-line data read-out (Phase III) trials in the first half of 2026 for VRDN-003 (subcutaneous/auto-injector application) and subsequent FDA-submission.

Veligrotug holds 'Breakthrough Therapy Designation' with implied shorter review time and favorable economics, if approved.

"We factor in an 80% approval probability and conservatively add ~C$1.20 NAV/~C$1.00 TP. We see the transaction as positive for DRI, given the track record of success and relatively low up-front capital for a high probability of success/reward as the M&A pipeline remains active."

Price: 14.87, Change: -0.32, Percent Change: -2.11